LioCyx (HBV antigen specific TCR redirected T cell therapy) / Lion TCR - LARVOL DELTA

Lion TCR Secures USD 40 million Series B2 Financing, Revolutionizing Solid Tumor Treatment with mRNA-Encoding TCR-T Cell Therapy (PRNewswire-Asia) - "27 June 2023, Lion TCR...is thrilled to announce the successful completion of its USD 40 million Series B2 financing round. Guangzhou Industrial Investment and Capital Operation Holding Group Ltd. led the financing with participation from Guangzhou Guoju Investment and CSPC NARD Capital Fund. The funds raised will be used primarily to support Lion TCR's clinical trials on hepatitis B virus (HBV)-specific TCR T cell therapy, while also facilitating the construction of a state-of-the-art GMP facility in China. This momentous achievement will further accelerate the development of cutting-edge technology platforms and the advancement of Lion TCR's product pipelines."

Financing • Oncology • Solid Tumor

[VIRTUAL] Phase I Study of LioCyx-M, Autologous Hepatitis B Virus (HBV)-Specific T cell receptor (TCR) T-cells, in Recurrent HBV-Related Hepatocellular Carcinoma (HCC) Post-Liver Transplantation (SITC 2020) - P1 | "Conclusions Our data showed that multiple infusions of LioCyx-M are well tolerated at all dose levels administrated in recurrent HCC post liver transplantation, with no adverse effect to the transplanted liver. This calls for further assessment in a Phase 2 study."

P1 data • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

[VIRTUAL] Use of LioCyx-M, Autologous Hepatitis B Virus (HBV)-Specific T cell receptor (TCR) T-cells, in Advanced HBV-related Hepatocellular Carcinoma (HCC) (SITC 2020) - P1 | "Conclusions The encouraging clinical outcome and tolerable safety highlight the good benefit-risk profile of LioCyx-M. Therefore, further exploration of efficacy of LioCyx-M treatment for advanced HBV-HCC is warranted in a Phase 2 proof-of-concept clinical study."

IO Biomarker • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation (clinicaltrials.gov) - P1/2 | N=0 | Withdrawn | Sponsor: Lion TCR Pte. Ltd. | N=72 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Gastrointestinal Cancer • Hepatitis B • Hepatocellular Cancer • Hepatology • Infectious Disease • Inflammation • Oncology • Solid Tumor • Transplantation

[VIRTUAL] Use of LioCyx-M, Autologous Hepatitis B Virus (HBV)-Specific T cell receptor (TCR) T-cells, in Advanced HBV-related Hepatocellular Carcinoma (HCC) (SITC 2020) - P1 | "Conclusions The encouraging clinical outcome and tolerable safety highlight the good benefit-risk profile of LioCyx-M. Therefore, further exploration of efficacy of LioCyx-M treatment for advanced HBV-HCC is warranted in a Phase 2 proof-of-concept clinical study."

IO Biomarker • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

[VIRTUAL] Phase I Study of LioCyx-M, Autologous Hepatitis B Virus (HBV)-Specific T cell receptor (TCR) T-cells, in Recurrent HBV-Related Hepatocellular Carcinoma (HCC) Post-Liver Transplantation (SITC 2020) - P1 | "Conclusions Our data showed that multiple infusions of LioCyx-M are well tolerated at all dose levels administrated in recurrent HCC post liver transplantation, with no adverse effect to the transplanted liver. This calls for further assessment in a Phase 2 study."

P1 data • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

[VIRTUAL] Phase 1 study of autologous hepatitis B virus (HBV)-specific T cell receptor (TCR) T-cells, LioCyx-M in unresectable HBV-related hepatocellular carcinoma (HCC) (DLCS 2021) - P1 | "Our data have demonstrated the on-target ability of LioCyx-M with promising clinical outcome and good safety profile. Further efficacy exploration of LioCyx-M for advanced HBV-HCC is required in a Phase 2 study."

IO biomarker • P1 data • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV) (clinicaltrials.gov) - P1; N=5; Not yet recruiting; Sponsor: Lion TCR Pte. Ltd.

Clinical • New P1 trial • Gastrointestinal Cancer • Hepatitis B • Hepatocellular Cancer • Hepatology • Infectious Disease • Oncology • Solid Tumor

[VIRTUAL] Immunological alterations induced by HBV-TCR T cell immunotherapy associates with treatment response of primary HBV related-HCC. (DLCS 2021) - "Immunological alterations in the peripheral blood induced by T cell immunotherapy is associated with treatment response. This has important implications in the monitoring of primary HBV-HCC patients receiving T cell immunotherapy."

Hepatocellular Cancer • CXCL10 • CXCL9

[VIRTUAL] Immunosuppressive Drug Resistant Armored TCR T cells for immune-therapy of HCC in liver transplant patients (DLCS 2021) - "We engineered TCR-T cells of desired specificities that transiently escape the immunosuppressive effects of TAC and MMF. This finding has important clinical applications for the treatment of HBV- HCC relapses and other pathologies occurring in organ transplanted patients."

Clinical • IO biomarker • Hepatocellular Cancer • ENTPD1

TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver Transplantation (clinicaltrials.gov) - P1; N=7; Active, not recruiting; Sponsor: Xiaoshun He

Clinical • New P1 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Oncology • Solid Tumor • Transplantation